📊 NNVC Key Takeaways
Is NNVC a Good Investment? Thesis Analysis
Nanoviricides is a pre-revenue pharmaceutical company with severe operational challenges, burning cash at an unsustainable rate while generating zero revenue. With only 5.2M in cash, negative operating cash flow of -3.6M annually, and no near-term revenue generation, the company faces critical liquidity risk within 12-18 months absent major financing or operational breakthroughs.
Why Buy NNVC? Key Strengths
- Strong current ratio of 4.43x provides short-term liquidity cushion
- Moderate debt-to-equity ratio of 0.43x shows conservative leverage
- Stockholders equity of 11.1M exceeds total liabilities indicating some balance sheet stability
NNVC Investment Risks to Consider
- Zero revenue generation with no apparent commercialized products in market
- Negative operating cash flow of -3.6M with only 5.2M cash reserves creates critical runway concern
- Persistent operating losses of -4.0M and ROE of -36.2% indicate fundamental business viability questions
- No insider buying activity in 90 days suggests lack of management confidence
- Long-term debt of 4.7M combined with cash burn creates refinancing risk
Key Metrics to Watch
- Cash burn rate and remaining runway to profitability or capital raise
- Revenue recognition or pipeline advancement in clinical development
- Operating cash flow trajectory and quarterly burn trends
- Debt maturity schedule and refinancing capacity
- Insider trading activity as indicator of management confidence
NNVC Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.43x current ratio provides a solid financial cushion.
NNVC Profitability Ratios
NNVC vs Healthcare Sector
How NANOVIRICIDES, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NNVC Overvalued or Undervalued?
Based on fundamental analysis, NANOVIRICIDES, INC. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NNVC Balance Sheet & Liquidity
NNVC 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: NANOVIRICIDES, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.70 indicates the company is currently unprofitable.
NNVC Growth Metrics (YoY)
NNVC Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | N/A | -$1.8M | $-0.11 |
| Q1 2026 | N/A | -$1.8M | $-0.10 |
| Q3 2025 | N/A | -$1.9M | $-0.14 |
| Q2 2025 | N/A | -$2.0M | $-0.14 |
| Q1 2025 | N/A | -$2.0M | $-0.17 |
| Q3 2024 | N/A | -$1.6M | $-0.15 |
| Q2 2024 | N/A | -$1.6M | $-0.15 |
| Q1 2024 | N/A | -$1.6M | $-0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NNVC Capital Allocation
NNVC SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for NANOVIRICIDES, INC. (CIK: 0001379006)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NNVC
What is the AI rating for NNVC?
NANOVIRICIDES, INC. (NNVC) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NNVC's key strengths?
Claude: Strong current ratio of 4.43x provides short-term liquidity cushion. Moderate debt-to-equity ratio of 0.43x shows conservative leverage.
What are the risks of investing in NNVC?
Claude: Zero revenue generation with no apparent commercialized products in market. Negative operating cash flow of -3.6M with only 5.2M cash reserves creates critical runway concern.
What is NNVC's revenue and growth?
NANOVIRICIDES, INC. reported revenue of $0.0.
Does NNVC pay dividends?
NANOVIRICIDES, INC. does not currently pay dividends.
Where can I find NNVC SEC filings?
Official SEC filings for NANOVIRICIDES, INC. (CIK: 0001379006) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NNVC's EPS?
NANOVIRICIDES, INC. has a diluted EPS of $-0.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NNVC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, NANOVIRICIDES, INC. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NNVC stock overvalued or undervalued?
Valuation metrics for NNVC: ROE of -36.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NNVC stock in 2026?
Our dual AI analysis gives NANOVIRICIDES, INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NNVC's free cash flow?
NANOVIRICIDES, INC.'s operating cash flow is $-3.6M, with capital expenditures of $84.3K.
How does NNVC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -36.2% (avg: 15%), current ratio 4.43 (avg: 2).